Furthermore, it was reported that CDC20 overexpression facilitates the docetaxel resistance of the castration-resistant prostate cancer (CRPC) cell lines in a Bim-dependent manner, indicating that the drugs targeting CDC20 were urgent to be developed for the treatment of the CRPC with docetaxel resistance (Wu et al., 2018). The gene discussed is BCL2L11; the disease is prostate cancer.